Great thanks for that info, very useful!Makes sense to focus on...

First 15 Last

Share
Profile

Follow
GazBusey

136 Posts.

53

09/01/25

14:01

Post #: 77334091
Share

Originally posted by KrushingIt: ↑

"Do you know of any progress or expected updates on the CAR-NK CDH17 program by Chimeric?"

My understanding was that Case Western, the developers of the CORE NK platform were progressing the pre clinical pipeline for a very modest fee in the US as of late 2023.

I believe the company was looking to onshore some of the pre clinical work relating to the CORE NK platform at Peter Mac institute in Melbourne given there are some NK experts there, the company can also claim a 43.5% R&D tax rebate and there is potential grant funding available.

Methinks the CORE NK pre clinical program inc CAR-NK CDH17 slowed down due to the company budget constraints.....methinks it makes to resume in earnest if CART CDH17 is demonstrating early efficacy, because it would be very appealing to any partners during a takeover or licensing discussion. Importantly, we should be able to leverage our CAR design in CART in the CORE NK therapy.

"Also I was looking on Arbele Bio site, and they state they own the patent to target CDH17 gastrointestinal cancers - do you know if this impacts Chimeric's addressable market??"

No impact. CHM has patents in place for CDH17 CART. The addressable market is only really impacted by the number of GI patients that are CDH17 positive (which is over 50% of GI cancers according to some studies). The further down the GI tract you go, the more CDH17 is overexpressed in cancer patients.

Expand

Great thanks for that info, very useful!

Makes sense to focus on the CAR-T CDH17, but agree that getting some proof of concept pre-clinical results for the CAR-NK would be terrific for any negotiation and could even help boost MC in itself.

CHM Price at posting: 0.7¢ Sentiment: Buy Disclosure: Not Held
1 Upvote

0 Great analysis

Reply

Top Stories

ASX Market Close: Bourse spins in circles as Israel-Iran conflict weighs | June 17, 2025

VBX Ltd jumps 15% on ASX debut as newest Oz bauxite player

MEM

Many are concerned about global falling birthrates. This diverse stock has solutions

RCE

Recce locks in $30M to boost commercialisation across ASEAN region

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

First 15 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 0.4¢		Change 0.000(0.00%)		Mkt cap ! $8.060M

Open	High	Low	Value	Volume
0.4¢	0.4¢	0.4¢	$100	25K

Buyers (Bids)

No.	Vol.	Price($)
28	21874000	0.4¢

Sellers (Offers)

Price($)	Vol.	No.
0.5¢	19510638	27

View Market Depth

No.	Vol.	Price($)
28	21874000	0.004
37	23631939	0.003
15	13500507	0.002
9	49600000	0.001
0	0	0.000

Price($)	Vol.	No.
0.005	19510638	27
0.006	23500718	17
0.007	4700000	4
0.008	8542434	6
0.009	2767672	5

Last trade - 15.25pm 17/06/2025 (20 minute delay)

CHM (ASX) Chart

Great thanks for that info, very useful!Makes sense to focus on...

ASX Market Close: Bourse spins in circles as Israel-Iran conflict weighs | June 17, 2025

VBX Ltd jumps 15% on ASX debut as newest Oz bauxite player

Many are concerned about global falling birthrates. This diverse stock has solutions

Recce locks in $30M to boost commercialisation across ASEAN region

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Great thanks for that info, very useful!Makes sense to focus on...

Top Stories

ASX Market Close: Bourse spins in circles as Israel-Iran conflict weighs | June 17, 2025

VBX Ltd jumps 15% on ASX debut as newest Oz bauxite player

Many are concerned about global falling birthrates. This diverse stock has solutions

Recce locks in $30M to boost commercialisation across ASEAN region

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News